InvestSMART

Tissue Repair Ltd (ASX:TRP)

ALERT: Price-sensitive ASX Announcement for TRP
Current share price for TRP : $0.082 -0.223 (-73.11%)+
Announcement
Release
29 Oct 2025 1:10PM
Price at Release
$0.305
Full Release
download
Summary
Tissue Repair Limited's quarterly activities report for the period ending 30 September 2025 details operational and financial updates. The company, a Phase 3 biotechnology firm, is advancing its TR987® for chronic wounds and commercializing TR Pro+®, a topical treatment designed to accelerate healing and improve skin quality. The financial summary indicates a cash position of $10.3 million with net operating cash outflows of approximately $1.97 million, largely due to R&D expenditures. Revenue from TR Pro+® sales increased to $202,000, and interest income was $23,000. Manufacturing updates include the completion of Glucoprime® API batches and a planned major production campaign for TR Pro+® in February 2026. The company is also progressing with regulatory submissions for US and EU market entry. Additionally, they have commenced partnerships, such as with Advanced Cosmeceuticals Pty Ltd, and are exploring new product formulations to expand their therapeutic portfolio.
Key Points
  • Tissue Repair Limited is a Phase 3 biotechnology company.
  • Focused on TR987® for chronic wounds and TR Pro+® for healing post-procedures.
  • Cash position at $10.3 million with $1.97 million net operating cash outflows.
  • TR Pro+® sales revenue increased to $202,000.
  • Plans for major TR Pro+® production campaign in February 2026.
  • Regulatory submissions for US and EU are underway.
  • Partnership with Advanced Cosmeceuticals Pty Ltd commenced.
  • Exploring new product formulations for market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.